Clinical Trial Update: Phase II Study of Gefitinib Plus Nimotuzumab Versus Gefitinib in Non-small Cell Lung Cancer [Phase 2]

View source ↗

Summary

This document reports a completed Phase II trial comparing Gefitinib plus Nimotuzumab versus Gefitinib alone in patients with Non-Small Cell Lung Cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Iressa (Gefitinib) (Gefitinib)
• Nimotuzumab (nimotuzumab)

Snippet

Sponsor: Yonsei University | Conditions: Non Small Cell Lung Cancer (NSCLC) | Phase 2 | Status: COMPLETED